Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
5.98
+0.45 (8.14%)
At close: Aug 4, 2026, 4:00 PM EDT
5.98
0.00 (0.04%)
Pre-market: Aug 5, 2026, 7:55 AM EDT

Aclaris Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
835363267741,050890
Market Cap Growth
404.13%35.61%259.31%-92.91%17.98%205.03%
Enterprise Value
646.39271.95153.87-44.67833.46699.54
Last Close Price
5.983.012.481.0515.7514.54
PS Ratio
99.8246.3514.292.3835.30131.68
PB Ratio
5.813.521.720.475.314.51
P/TBV Ratio
5.173.581.230.475.394.34
EV/Sales Ratio
77.2534.758.22-1.4328.01103.47
EV/EBITDA Ratio
---0.46--
EV/EBIT Ratio
---0.46--
EV/FCF Ratio
---0.56--
Net Debt / Equity Ratio
-0.73-0.88-0.73-0.76-1.10-0.97
Net Debt / EBITDA Ratio
1.321.200.811.232.442.15
Net Debt / FCF Ratio
2.021.925.631.503.183.64
Asset Turnover
0.050.040.090.140.120.04
Quick Ratio
4.033.363.993.869.948.37
Current Ratio
4.033.363.994.1610.558.94
Return on Equity (ROE)
-56.47%-50.20%-84.46%-49.88%-44.01%-77.34%
Return on Assets (ROA)
-44.81%-40.11%-67.95%-42.90%-35.53%-55.73%
Return on Invested Capital (ROIC)
-318.34%-281.35%-354.68%-1031.05%--12872.72%
Return on Capital Employed (ROCE)
-53.10%-47.65%-79.92%-48.79%-38.99%-63.14%
Buyback Yield / Dilution
-37.77%-58.56%-10.73%-7.05%-14.95%-33.36%
Total Shareholder Return
-37.77%-58.56%-10.73%-7.05%-14.95%-33.36%
SEC Filings: 10-K · 10-Q